Latest Radius Residential Care (NZX:RAD) News

Cann Group, OncoSil and Imugene led a busy healthcare week as investors chased FDA steps, cancer trial news and balance-sheet fixes. Elsewhere, revenue growth, hospital contracts and fresh funding kept money flowing into names with near-term commercial milestones.

Radius Residential Care boosted its profit before tax by 37% to $14.3 million in FY26, driven by strong operational performance and strategic acquisitions. The group now operates over 2,000 beds across 25 care homes and four villages, with a focus on high-acuity care and diversified services including home support and catering.

Biotech names led healthcare trading this week, with Noxopharm, Acrux and TruScreen posting the biggest moves after clinical, licensing and expansion updates. Stronger cash flow, fresh capital and new contracts also lifted sentiment across medtech, aged care and healthcare services.

Radius Residential Care has syndicated its bank debt, boosting facility limits by NZD 30 million and cutting financing costs by 65 basis points to support its growth plans, including a new care home acquisition and development projects.

Capital raisings, resource updates and Medicare news drove the week’s biggest share moves. The sharpest gains came from silver and tungsten juniors, while the heaviest fall came from a deeply discounted equity raising.

Radius Residential Care delivered a standout FY26 with profit before tax surging 37% to $14.3 million, a 50% hike in its final dividend, and growth fueled by acquisitions and new developments.